NCT05548062Active, not recruiting
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
Prospective Observational Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis. This is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 242 (actual)
- First submitted
- 16 Sept 2022
- Start date
- 2 Mar 2023
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05548062
What you commit to
- Study type: Observational
- Participants enrolled: 242
- From 2 Mar 2023 to the primary completion date, 31 Aug 2027
- 30 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Signed informed consent must be obtained prior to participation in the study.
- Age ≥18 years.
- Diagnosis of PV according to WHO 2008 or WHO 2016 and high-risk stratification according to European LeukemiaNet (ELN) classification.
- At least one TE after diagnosis or up to 2 years prior to diagnosis.
- Patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (30)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.